Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035633 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00035633: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00035633 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035633, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
Interventions
- DRUG Entecavir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
What the finished NCT00035633 record still lists
NCT00035633 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Entecavir is the first listed.
NCT00035633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035633 about?
NCT00035633 is a clinical study titled "A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen". The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
What is the current status of trial NCT00035633?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00035633?
The interventions under investigation include: Entecavir (DRUG).
Who is sponsoring clinical trial NCT00035633?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia